A syndicate of international investors has raised $75 million for Code Biotherapeutics Inc, a US company developing genetic medicines using a synthetic DNA delivery platform. The delivery technology is different from the conventional viral vector and is described by its developer as versatile and unimpaired by concerns about immunogenicity.
